Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib.
Takahashi N, Miura M, Kuroki J, Mitani K, Kitabayashi A, Sasaki O, Kimura H, Imai K, Tsukamoto N, Noji H, Kondo T, Motegi M, Kato Y, Mita M, Saito H, Yoshida C, Torimoto Y, Kimura T, Wano Y, Nomura J, Yamamoto S, Mayama K, Honma R, Sugawara T, Sato S, Shinagawa A, Abumiya M, Niioka T, Harigae H, Sawada K. Takahashi N, et al. Among authors: abumiya m. Biomark Res. 2014 Mar 20;2(1):6. doi: 10.1186/2050-7771-2-6. Biomark Res. 2014. PMID: 24650752 Free PMC article.
Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy.
Fukuda N, Akamine Y, Abumiya M, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N, Miura M. Fukuda N, et al. Among authors: abumiya m. Cancer Chemother Pharmacol. 2022 May;89(5):609-616. doi: 10.1007/s00280-022-04419-1. Epub 2022 Mar 22. Cancer Chemother Pharmacol. 2022. PMID: 35316401
Phase II Clinical Trial of Lenalidomide and Dexamethasone Therapy in Japanese Elderly Patients With Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide.
Kobayashi T, Miura M, Niioka T, Abumiya M, Ito F, Kobayashi I, Ikeda S, Yoshioka T, Kameoka Y, Takahashi N. Kobayashi T, et al. Among authors: abumiya m. Ther Drug Monit. 2018 Jun;40(3):301-309. doi: 10.1097/FTD.0000000000000499. Ther Drug Monit. 2018. PMID: 29494421 Clinical Trial.
20 results